Characteristics of the patients with PsA
| n=120 | |
| Age (years)—median (IQR) | 50.5 (35–62) |
| Sex, female—n (%) | 84 (70) |
| North European ethnicity—n (%) | 111 (92.5) |
| Age at first diagnosis of psoriasis/psoriasis arthritis—median (IQR) | 33.5 (21–43) |
| Psoriasis—n (%) | 96 (80) |
| Pustular psoriasis—n (%) | 13 (10) |
| Nail psoriasis—n (%) | 9 (7.5) |
| Axial SpA—n (%) | 35 (29.2) |
| Enthesiopathy—n (%) | 35 (29.2) |
| Dactylitis—n (%) | 11 (9.5) |
| Anterior uveitis—n (%) | 6 (5) |
| IBD—n (%) | 5 (4.2) |
| Treatment | |
| NSAID monotherapy—n (%) | 12 (10) |
| csDMARD—n (%) | 59 (49.2) |
| TNFi—n (%) | 27 (22.5) |
| IL-17i—n (%) | 19 (15.8) |
| IL-23i*—n (%) | 6 (5) |
| JAKi—n (%) | 10 (8.3) |
| Other†—n (%) | 5 (4.2) |
*Including treatment with ustekinumab, targeting both IL-23 and IL-12.
†Including apremilast or bDMARDs not listed above.
bDMARD, biological disease-modifying antirheumatic drugs; csDMARD, conventional synthetic disease-modifying antirheumatic drugs; DMARD, disease-modifying antirheumatic drug; IBD, inflammatory bowel disease; IL-17i, interleukin 17 inhibitor; IL-23i, interleukin 23 inhibitor; JAKi, janus kinase inhibitor; n, number; NSAID, non-steroidal anti-inflammatory drug; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitor.